Prostate Cancer Review
We want to congratulate members of our group for publishing a review article, “A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer,” in Drug Discovery Today (June 2025). The review evaluates the efficacy of both established and emerging prostate cancer (PCa) therapies in the context of treatment resistance, a major clinical challenge that frequently drives progression to castration-resistant prostate cancer (CRPC).
By organizing current therapeutic options through the lens of resistance mechanisms, this article provides a practical framework for understanding why standard treatments can lose effectiveness and how next-generation strategies may help address these limitations. The review discusses key resistance drivers such as AR mutations, AR pathway amplification and signalling crosstalk, and tumour microenvironment (TME) maintenance, while also highlighting how clinical resistance evidence can inform therapy development and selection in the coming decade.
Review Highlights:
- Traditional and emerging prostate cancer (PCa) therapies to guide therapy selection are collated.
- PCa therapies are explored through the lens of resistance mechanisms in chemotherapy, hormone, targeted, and protein degradation therapy.
- Mechanisms driving PCa resistance are outlined, including AR mutations, AR crosstalk and amplification, and TME maintenance.
- Existing PCa clinical resistance data can be leveraged to guide PCa therapies over the next 10 to 20 years.
Please cite this article as: Zhang, S., Zhang, T., Kinsella, G. & Curtin, J. A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer. Drug Discovery Today (2025), 104384. https://doi.org/10.1016/j.drudis.2025.104384
